行情

MBRX

MBRX

Moleculin
NASDAQ

实时行情|Nasdaq Last Sale

1.010
-0.010
-0.98%
盘后: 1.020 +0.01 +0.99% 16:39 12/11 EST
开盘
1.030
昨收
1.020
最高
1.030
最低
1.010
成交量
19.11万
成交额
--
52周最高
3.150
52周最低
0.7772
市值
4,618.50万
市盈率(TTM)
-2.8032
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MBRX 新闻

  • UPDATE 2-Mexico's Televisa wins injunction on part of Disney-Fox deal; merger unaffected
  • Reuters.6天前
  • UPDATE 1-Televisa wins injunction over Disney purchase of Fox assets in Mexico
  • Reuters.6天前
  • Hedge fund titan Steve Cohen in talks to increase his stake in Mets
  • CNBC.com.12/04 20:44
  • GPRO, CLVS among premarket gainers
  • Seeking Alpha - Article.12/04 14:11

更多

所属板块

制药
+0.17%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

MBRX 简况

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.
展开

Webull提供Moleculin Biotech Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。